A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
Bio-Thera and STADA expand biosimilars partnership to include tocilizumab
Shilpa Medicare secures approval for NAFLD therapy NorUDCA in India
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
Seragon launches Enlivien sleep and longevity optimiser
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
Fosun Pharma agrees XH-S004 overseas licensing deal
Novartis reports positive Phase III results for ianalumab in Sjögren's disease
CivicaScript to distribute biosimilar for chronic inflammatory conditions
MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241
Formation Bio licenses IMIDomics' anti-CD226 autoimmune programme
Vascarta names Dr. Janet Loesberg as fractional chief strategy officer
Hengrui Pharma and GSK to jointly develop up to 12 innovative medicines